Lanatoside C inhibits Wnt/β-catenin signaling by down-regulating c-Myc in gastric cancer cells, while overexpression of c-Myc reverses the anti-tumor effect of lanatoside C, suggesting that c-Myc is a key drug target of lanatoside C (Hu et al., 2018). This evidence concerns the gene MYC and neoplasm.